Brain Health

Adam Kahleifeh, PharmD, BCOP, discusses the impact of IDH mutations in low-grade gliomas.

The authors wrote that patients with CKD under the age of 60 years may be at a greater risk of depression.

New intravenous formulation GTx-104 shows promise in improving brain health outcomes for patients with aSAH, offering safer treatment options for pharmacists.

Researchers uncover a brain circuit linking stress to increased blood glucose, revealing insights into stress's role in type 2 diabetes (T2D) development.

Investigators emphasize that early cardiovascular risk assessments and preventive strategies are necessary for women with polycystic ovarian syndrome (PCOS).

FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.

Women using depot medroxyprogesterone acetate face a significantly higher risk of meningioma, especially with long-term use or starting after age 31.

Moderate-to-severe TBI significantly increases the risk of malignant brain tumors, highlighting the need for long-term monitoring in survivors.

The subcutaneous injection for maintenance treatment enhances accessibility and reduces infusion time for patients.

The new data highlight how dietary changes could fuel Alzheimer- and dementia-related mechanisms.

The complete response letter (CRL) stated that vatiquinone's new drug application (NDA) did not provide substantial evidence of efficacy and would need to be evaluated in a new trial.

By improving low-density lipoprotein cholesterol (LDL-C) levels, statins reduced complications after pipeline embolization device implantation for intracranial aneurysms.

New research confirms oseltamivir (Tamiflu; Roche) is safe for children, reducing flu-related neuropsychiatric risks and encouraging timely antiviral treatment.

Harvard researchers reveal lithium deficiency as a potential early driver of Alzheimer disease, suggesting new treatment avenues for patients.

Pharmacists play a crucial role in managing headaches in patients on complement inhibitors for PNH, ensuring proper education and risk mitigation strategies.

The FDA approves dordaviprone, the first systemic therapy for H3 K27M-mutant diffuse midline glioma, offering hope for patients with limited options.

New research reveals that GLP-1 receptor agonists like semaglutide may significantly reduce stroke impacts and improve recovery outcomes.

Hospitalized older adults infected with SARS-CoV-2 had faster declines in executive function and memory compared with both uninfected and nonhospitalized infected patients.

Sepiapterin treatment allowed patients to liberalize their diet while reaching or exceeding recommended daily protein allowances in patients living with phenylketonuria.

VMAT2 inhibitors can improve movement symptoms.

New research links gabapentin use for back pain to increased dementia risk, especially in middle-aged adults.

A direct link between memories and physical changes has not yet been established.

Amyvid is used for brain imaging to estimate amyloid plaque density in patients with cognitive impairment undergoing evaluation for Alzheimer disease.

A recent meta-analysis reveals low persistence rates with anti-dementia drugs, highlighting factors influencing adherence and the need for standardized reporting.